Screening for drug safety

Description
Gallery
  • Project Lead(s): Peter Zandstra

    Counterfeit and substandard drugs are increasingly pervasive in developing nations. Current testing methods cannot identify compounds that are not normally present when the drug is produced, including harmful contaminants that can arise if the drug is improperly made or counterfeit.

    A stem cell-based drug testing platform will allow healthcare workers in developing communities to identify the source of counterfeit-drug induced illnesses at ultra-low cost with the same high standards used by pharmaceutical companies.

  • 0564-01-10 Peter Zandstra Bioreactor

    0564-01-10 Peter Zandstra Bioreactor

    0564-01-10 Peter Zandstra Human Embryonic Stem Cell-Derived Cardiomycoytes

    0564-01-10 Peter Zandstra Human Embryonic Stem Cell-Derived Cardiomycoytes

    0564-01-10 Peter Zandstra Drug Screen Schematic

    0564-01-10 Peter Zandstra Drug Screen Schematic

    0564-01-10 Bioreactor Devce

    0564-01-10 Bioreactor Devce